StreetAlpha.app
Home › Stocks › SNDX

Syndax Pharmaceuticals Inc (SNDX)

Healthcare
$9.20
▲ +0.77%
LAST CLOSE · NOV 17

Syndax Pharmaceuticals develops and sells cancer medicines, including Revuforj for certain acute leukemias. It last closed at $9.20 on Nov 17, up 0.77% on the day. The average 12-month price target from 2 analysts is $34.50 (+275.0% from the last close), with a high of $36.00 and a low of $33.00. In the past 30 days there were 2 dark pool prints totaling $1.5M, the largest $1.1M.

AI Auto Pilots
Is SNDX in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$289.7M
+160.3% vs a year ago
Net income
−$209.5M
−72.3% margin
EPS (diluted)
−$2.37
Operating margin
−61.7%
−$178.6M operating income
Valuation
Market cap
$821.5M
89.3M shares
P/E
–
No P/E while losing money
Price to sales
2.8
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$135.9M
At Sep 30
Debt
$594.2M
At Sep 30
Shareholder equity
−$17.2M
Shares outstanding
89.3M
At Jul 31
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $139.7M$139.7MFY2021FY2022: $0$0FY2022FY2023: $0$0FY2023FY2024: $23.7M$23.7MFY2024FY2025: $172.4M$172.4MFY2025

From SNDX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 2). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
2 Buy
2 firms · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
2 Buy
2firms
2 Buy0 Hold0 Sell
Only 2 firms rated SNDX in the past 90 days, not enough for a consensus
Average 12-month target
$34.50
▲ 275.0% upside

Based on 2 analysts who set a price target on SNDX in the past 90 days. The average target is $34.50, with a high of $36.00 and a low of $33.00, compared with the last close of $9.20.

Low $33.00Avg $34.50High $36.00
Blue marker: last close $9.20
Highest target$36.00
Average target$34.50
Lowest target$33.00
Latest rating changes
HC Wainwright & Co.Target lowered
Nov 3Buy$38 → $36
HC Wainwright & Co.Reiterated
Oct 13Buy$38
UBSMaintained
Aug 21Buy$33
JP MorganMaintained
Aug 11Buy$40
HC Wainwright & Co.Target lowered
Aug 5Buy$40 → $38
DateFirmActionRatingPrice target
Nov 3HC Wainwright & Co.Target loweredBuy$38 → $36
Oct 13HC Wainwright & Co.ReiteratedBuy$38
Aug 21UBSMaintainedBuy$33
Aug 11JP MorganMaintainedBuy$40
Aug 5HC Wainwright & Co.Target loweredBuy$40 → $38
Loading…

Technical Analysis

SNDX · as of the Nov 17 close · updated after every close
Downtrend, oversold

The stock is 26% below its 20 day and 61% below its 50 day average. It is 113% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 26), oversold. The nearest support is the swing low (Nov 9) at $9.15, and the nearest resistance the Pivot at $9.24.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 9.2%/day
Key levels
$25.5952 week high+178.2%
$19.61200 day average+113.2%
$17.87100 day average+94.2%
$14.8350 day average+61.2%
$11.5920 day average+26.0%
$9.93Swing high (Nov 12)+7.9%
$9.45Pivot R1+2.7%
$9.24Pivot+0.4%
$9.20Last close
$9.15Swing low (Nov 9)−0.5%
$9.0352 week low−1.8%
$8.99Pivot S1−2.3%
Indicators
RSI (14)25.81Oversold below 30Oversold
MACD-1.72Below its signal lineBearish
Stochastic3.4Near the bottom of its rangeOversold
ADX (14)48.2Strong downtrend
Williams %R-97.0Oversold below −80, overbought above −20Oversold
CCI (20)-82.4Oversold below −100, overbought above 100Neutral
Rate of change−35.6%Change over 10 sessionsBearish
ATR (14)$0.85Typical daily range, 9.2% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for SNDX

What happened before

See how SNDX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow SNDX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How SNDX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2016.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in SNDX in the last 90 days.

Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
2
Notional
$1.5M
Largest print
$1.1M
Loading…

SNDX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ●110 buying vs 122 selling
  • ▼Held by funds -10.6 pts
  • ▼Funds holding -5
  • ▼Superinvestors: 0 added, 3 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding237242−2.1%
In funds' top 101011−9.1%
Held by funds110.5%121.1%−10.6 pts
New / increased31 / 7934 / 96−15.4%
Reduced / sold out86 / 3675 / 40+6.1%
Put/call ratio0.020.00+2424.8%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See SNDX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether SNDX is in one of them and how their past SNDX trades turned out.

SNDX in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered SNDX in an article yet. Here's the latest on the wider market.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals is a biopharmaceutical company based in New York that develops and sells cancer treatments. Its two approved medicines are Revuforj, a pill for certain acute leukemias, and Niktimvo, used to treat chronic graft versus host disease. Syndax leads sales of Revuforj in the United States and works with partner Incyte on Niktimvo. Its customers are cancer patients and the doctors who treat them.

Headquarters
New York, NY